{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:32:51Z","timestamp":1782927171377,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xops.2024.100565","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:15:57Z","timestamp":1718669757000},"page":"100565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study"],"prefix":"10.1016","volume":"4","author":[{"given":"Zufar","family":"Mulyukov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9239-745X","authenticated-orcid":false,"given":"Pearse A.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-4372","authenticated-orcid":false,"given":"Sandra","family":"Liakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0310","authenticated-orcid":false,"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Shu","family":"Wei Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gallego-Pinazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming","family":"Gemmy Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-6942","authenticated-orcid":false,"given":"Gabriella","family":"De Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oudy","family":"Semoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-442X","authenticated-orcid":false,"given":"G\u00e1bor M\u00e1rk","family":"Somfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Lujan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lorand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.xops.2024.100565_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","article-title":"Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service","volume":"33","author":"Gale","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.xops.2024.100565_bib2","series-title":"Wet age-related macular degeneration (wet AMD) [Internet]","author":"Hobbs","year":"2022"},{"key":"10.1016\/j.xops.2024.100565_bib3","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration","volume":"15","author":"Hussain","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.xops.2024.100565_bib4","author":"Duffy"},{"key":"10.1016\/j.xops.2024.100565_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","article-title":"Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence","volume":"105","author":"Daien","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100565_bib6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti\u2013vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2024.100565_bib7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","article-title":"Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group","volume":"36","author":"Arevalo","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100565_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity Outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100565_bib9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100565_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100565_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian Treat-and-Extend analysis Trial with Ranibizumab Study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100565_bib12","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100565_bib13","article-title":"Use of imaging modalities in real life: impact on visual acuity outcomes of ranibizumab treatment for neovascular age-related macular degeneration in Germany","volume":"2020","author":"Wachtlin","year":"2020","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.xops.2024.100565_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100972","article-title":"AI-based monitoring of retinal fluid in disease activity and under therapy","volume":"86","author":"Schmidt-Erfurth","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2024.100565_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100565_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100565_bib17","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41433-021-01487-0","article-title":"Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations","volume":"35","author":"Kodjikian","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.xops.2024.100565_bib18","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s40123-023-00768-z","article-title":"Systematic review of neovascular age-related macular degeneration disease activity criteria use to shorten, maintain or extend treatment intervals with anti-VEGF in clinical trials: implications for clinical practice","volume":"12","author":"Patel","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.xops.2024.100565_bib19","first-page":"1573","article-title":"ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)","volume":"104","author":"Liakopoulos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100565_bib20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/IAE.0000000000000483","article-title":"Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"35","author":"Toth","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100565_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/ICU.0000000000000782","article-title":"Artificial intelligence-based predictions in neovascular age-related macular degeneration","volume":"32","author":"Ferrara","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.xops.2024.100565_bib22","first-page":"5428","article-title":"A\u00a0preliminary study of predicting effectiveness of anti-VEGF injection using OCT images based on deep learning","author":"Feng","year":"2020","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"key":"10.1016\/j.xops.2024.100565_bib23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.oret.2021.01.009","article-title":"Predicting incremental and future visual change in neovascular age-related macular degeneration using deep learning","volume":"5","author":"Fu","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100565_bib24","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1109\/JBHI.2020.3000136","article-title":"End-to-end deep learning model for predicting treatment requirements in neovascular AMD from longitudinal retinal OCT imaging","volume":"24","author":"Romo-Bucheli","year":"2020","journal-title":"IEEE J Biomed Health Inform"},{"key":"10.1016\/j.xops.2024.100565_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100565_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.10.4.17","article-title":"Automated quantification of pathological fluids in neovascular age-related macular eegeneration, and its repeatability using deep learning","volume":"10","author":"Mantel","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100565_bib27","author":"Apostolopoulos"},{"key":"10.1016\/j.xops.2024.100565_bib29","series-title":"RetinAI Discovery\u00ae","year":"2024"},{"key":"10.1016\/j.xops.2024.100565_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/001316447003000105","article-title":"Estimating the reliability, systematic error and random error of interval data","volume":"30","author":"Krippendorff","year":"1970","journal-title":"Educ Psychol Meas"},{"key":"10.1016\/j.xops.2024.100565_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100031","article-title":"Reliability of subjective assessment of SD-OCT pathologies by multiple raters in retinal vein occlusion","volume":"1","author":"Bemme","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2024.100565_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12938-016-0206-x","article-title":"Retinal status analysis method based on feature extraction and quantitative grading in OCT images","volume":"15","author":"Fu","year":"2016","journal-title":"Biomed Eng Online"},{"key":"10.1016\/j.xops.2024.100565_bib33","author":"Bracha"},{"key":"10.1016\/j.xops.2024.100565_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","article-title":"Fully automated detection and quantification of macular fluid in OCT using deep learning","volume":"125","author":"Schlegl","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100565_bib35","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","article-title":"Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration","volume":"127","author":"Schmidt-Erfurth","year":"2020","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:03:02Z","timestamp":1732698182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914524001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666914524001015"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2024.100565","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2024.100565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100565"}}